Phil Nadeau
Stock Analyst at TD Cowen
(2.79)
# 1,712
Out of 5,143 analysts
25
Total ratings
50%
Success rate
32.5%
Average return
Main Sectors:
Stocks Rated by Phil Nadeau
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Maintains: Buy | $175 → $215 | $196.34 | +9.50% | 7 | Feb 9, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $175 → $200 | $128.38 | +55.79% | 1 | Dec 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $50 → $45 | $22.47 | +100.27% | 1 | Oct 31, 2025 | |
| KURA Kura Oncology | Reiterates: Buy | n/a | $8.35 | - | 1 | Nov 21, 2024 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $55 → $65 | $96.35 | -32.54% | 2 | Nov 6, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $125 → $120 | $62.92 | +90.72% | 1 | Aug 6, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $500 | $481.01 | +3.95% | 7 | Jul 23, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Outperform | n/a | $27.45 | - | 1 | Mar 3, 2023 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | n/a | $18.68 | - | 1 | Jul 7, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | n/a | $5.48 | - | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.89 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $6.75 | - | 1 | Jul 16, 2018 |
Biogen
Feb 9, 2026
Maintains: Buy
Price Target: $175 → $215
Current: $196.34
Upside: +9.50%
Neurocrine Biosciences
Dec 5, 2025
Maintains: Buy
Price Target: $175 → $200
Current: $128.38
Upside: +55.79%
Apellis Pharmaceuticals
Oct 31, 2025
Maintains: Buy
Price Target: $50 → $45
Current: $22.47
Upside: +100.27%
Kura Oncology
Nov 21, 2024
Reiterates: Buy
Price Target: n/a
Current: $8.35
Upside: -
Rhythm Pharmaceuticals
Nov 6, 2024
Maintains: Buy
Price Target: $55 → $65
Current: $96.35
Upside: -32.54%
BioMarin Pharmaceutical
Aug 6, 2024
Maintains: Buy
Price Target: $125 → $120
Current: $62.92
Upside: +90.72%
Vertex Pharmaceuticals
Jul 23, 2024
Maintains: Buy
Price Target: $450 → $500
Current: $481.01
Upside: +3.95%
Enliven Therapeutics
Mar 3, 2023
Initiates: Outperform
Price Target: n/a
Current: $27.45
Upside: -
MoonLake Immunotherapeutics
Jul 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $18.68
Upside: -
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.48
Upside: -
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $4.89
Upside: -
Jul 16, 2018
Initiates: Outperform
Price Target: n/a
Current: $6.75
Upside: -